TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$115 Million

Zymergen Inc.

Initial Public Offering

Bookrunner, March 2021

Zymergen Inc.

Zymergen Inc. (“Zymergen” or the “Company”) is a synthetic biology company that designs, develops and commercializes bio-differentiated breakthrough products across various end-markets. The Company creates new products with a proprietary platform that unlocks the design and manufacturing efficiency of biological processes with technology’s ability to rapidly iterate and control diverse functions. Zymergen’s technology platform is the engine that enables product innovation, using previously inaccessible biomolecules that can scale to commercial production.